Advertisement
MBAI vs XWEL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBAI is a Hold and XWEL is a Buy.
MBAI's RSI Indicator sits in oversold zone for 2 days
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBAI advanced for three days, in 164 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MBAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBAI as a result. In 83 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for MBAI moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBAI entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.530) is normal, around the industry mean (15.561). P/E Ratio (-0.790) is within average values for comparable stocks, (54.477). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.209) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (103.889).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MBAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
XWEL sees MACD Histogram crosses below signal line
XWEL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 42 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XWEL as a result. In 78 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 50-day moving average for XWEL moved below the 200-day moving average on September 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XWEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for XWEL entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for XWEL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where XWEL advanced for three days, in 161 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
XWEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.025) is normal, around the industry mean (64.051). P/E Ratio (-0.125) is within average values for comparable stocks, (1.569). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.220) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. XWEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XWEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
MBAI | XWEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 8 | 100 | |
PRICE GROWTH RATING 1..100 | 97 | 83 | |
P/E GROWTH RATING 1..100 | 98 | 13 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MBAI's Valuation (33) in the Medical Specialties industry is in the same range as XWEL (52) in the Other Consumer Services industry. This means that MBAI’s stock grew similarly to XWEL’s over the last 12 months.
MBAI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that MBAI’s stock grew similarly to XWEL’s over the last 12 months.
MBAI's SMR Rating (8) in the Medical Specialties industry is significantly better than the same rating for XWEL (100) in the Other Consumer Services industry. This means that MBAI’s stock grew significantly faster than XWEL’s over the last 12 months.
XWEL's Price Growth Rating (83) in the Other Consumer Services industry is in the same range as MBAI (97) in the Medical Specialties industry. This means that XWEL’s stock grew similarly to MBAI’s over the last 12 months.
XWEL's P/E Growth Rating (13) in the Other Consumer Services industry is significantly better than the same rating for MBAI (98) in the Medical Specialties industry. This means that XWEL’s stock grew significantly faster than MBAI’s over the last 12 months.
| MBAI | XWEL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| MACD ODDS (%) | N/A | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 10 days ago 77% | 14 days ago 78% |
| Declines ODDS (%) | 3 days ago 90% | 1 day ago 88% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBAI’s FA Score shows that 2 FA rating(s) are green while XWEL’s FA Score has 1 green FA rating(s).
- MBAI’s FA Score: 2 green, 3 red.
- XWEL’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBAI’s TA Score shows that 4 TA indicator(s) are bullish while XWEL’s TA Score has 4 bullish TA indicator(s).
- MBAI’s TA Score: 4 bullish, 4 bearish.
- XWEL’s TA Score: 4 bullish, 5 bearish.
Price Growth
MBAI (@Computer Communications) experienced а -22.30% price change this week, while XWEL (@Medical Specialties) price change was -17.65% for the same time period.
The average weekly price growth across all stocks in the @Computer Communications industry was -3.51%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +4.48%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.12%. For the same industry, the average monthly price growth was -4.99%, and the average quarterly price growth was +43.90%.
Reported Earning Dates
MBAI is expected to report earnings on Nov 23, 2026.
XWEL is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Computer Communications (-3.51% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
@Medical Specialties (-1.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
MBAI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBAI has been loosely correlated with BNAI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MBAI jumps, then BNAI could also see price increases.
| Ticker / NAME | Correlation To MBAI | 1D Price Change % | ||
|---|---|---|---|---|
| MBAI | 100% | +6.76% | ||
| BNAI - MBAI | 35% Loosely correlated | -6.82% | ||
| QTEX - MBAI | 29% Poorly correlated | +4.29% | ||
| TWST - MBAI | 26% Poorly correlated | +2.10% | ||
| NN - MBAI | 25% Poorly correlated | +0.42% | ||
| WRBY - MBAI | 25% Poorly correlated | +2.52% | ||
More | ||||
XWEL and
Correlation & Price change
A.I.dvisor tells us that XWEL and LUCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and LUCY's prices will move in lockstep.
| Ticker / NAME | Correlation To XWEL | 1D Price Change % | ||
|---|---|---|---|---|
| XWEL | 100% | -8.86% | ||
| LUCY - XWEL | 29% Poorly correlated | +4.12% | ||
| DRIO - XWEL | 28% Poorly correlated | -9.13% | ||
| XRAY - XWEL | 23% Poorly correlated | +5.34% | ||
| NVCR - XWEL | 22% Poorly correlated | +5.51% | ||
| MBAI - XWEL | 21% Poorly correlated | +6.76% | ||
More | ||||